tradmap

NMRA Earnings Neumora Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$5 -$2 $0 2022 2023 2024 2025
EPS
Net income (annual)
-$236M $4M $244M $0 2022 2023 2024 2025
Net income
Return on equity (annual)
-50% 89% 228% 0% 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$4 -$2 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$109M -$54M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-97% -48% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–16 of 16
Q2 20262026-06-30-0.532026-08-1410-Q
Q1 20262026-03-31-0.302026-05-0710-Q
FY 20252025-12-31-1.452026-03-3010-K
Q3 20252025-09-30-1.102025-11-0610-Q
Q2 20262025-06-30-0.752026-08-1410-Q
Q1 20262025-03-31-0.422026-05-0710-Q
FY 20252024-12-31-1.532026-03-3010-K
Q3 20252024-09-30-1.162025-11-0610-Q
Q2 20252024-06-30-0.712025-08-0610-Q
Q1 20252024-03-31-0.342025-05-1210-Q
FY 20242023-12-31-3.632025-03-0310-K
Q3 20242023-09-30-3.592024-11-1210-Q
Q2 20242023-06-30-2.502024-08-0610-Q
Q1 20242023-03-31-1.222024-05-0710-Q
FY 20242022-12-31-4.812025-03-0310-K
Q3 20232022-09-30-3.832023-11-0110-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.